Avidity Biosciences, Inc.
RNAHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $18.8M | $10.9M | $9.6M | $9.2M | $9.3M | $6.8M |
| Operating income | −$745.9M | −$378.9M | −$235.6M | −$178.9M | −$118.1M | −$44.3M |
| Net income | −$684.6M | −$322.3M | −$212.2M | −$174.0M | −$118.0M | −$44.4M |
| Total assets | $1.96B | $1.56B | $628.6M | $638.8M | $427.6M | $333.9M |
| Total liabilities | $269.4M | $138.9M | $127.8M | $60.7M | $46.1M | $27.7M |
| Equity | $1.69B | $1.42B | $500.8M | $578.1M | $381.4M | $306.2M |
| EPS (diluted) | $-4.97 | $-2.89 | $-2.91 | $-3.34 | $-2.85 | $-2.05 |
| Shares out. | 120.2M | 79.7M | 70.8M | 47.8M | 37.6M | 37.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −3977.3%
- Net margin
- −3650.4%
- Return on equity
- −40.5%
- Return on assets
- −35.0%
- Return on capital (ROCE)
- −42.3%
- Liabilities / assets
- 13.8%
- Debt / equity
- 0.16×
- Book value / share
- $14.05
- Revenue growth (YoY)
- 72.1%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 6.76safe
- Accruals / assets
- −1.7%clean
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 warning● 4 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2026-08Global Study of Del-desiran for the Treatment of DM1
- Phase 2Active Not Recruitingreadout ~2027-04-30Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping
- Phase 3Recruitingreadout ~2028-05A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
- Phase 3Not Yet Recruitingreadout ~2029-05A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
- Phase 2Active Not Recruitingreadout ~2030-04Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
- Phase 3Enrolling By Invitationreadout ~2030-08Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 3.7M | 21.2 | +8.9% |
| Apr 30, 2026 | 3.4M | 8.7 | +13.6% |
| Apr 15, 2026 | 3.0M | 6.0 | +57.6% |
| Mar 31, 2026 | 1.9M | 2.9 | +61.5% |
| Mar 13, 2026 | 1.2M | 1.0 | +173.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsFeb 27, 2026
- Shareholder voteFeb 26, 2026
- Other material eventFeb 23, 2026
- Regulation FD disclosure · Other material eventFeb 3, 2026
- Director / officer change · Other material eventDec 18, 2025
- Results of operationsNov 10, 2025
- Entered a material agreement · Regulation FD disclosureOct 27, 2025
- Other material eventOct 14, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Corporate family
Spin-offs from Avidity Biosciences, Inc. (1)
- Atrium Therapeutics, Inc.RNAupcomingFeb 17, 2026details
From the spin-off filings we track. Follow a company to walk its own history.